Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24;12(6):1309.
doi: 10.3390/diagnostics12061309.

Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence

Guido Rovera  1 , Serena Grimaldi  1 , Sara Dall'Armellina  1 , Roberto Passera  1 , Marco Oderda  2 , Giuseppe Carlo Iorio  3 , Alessia Guarneri  3 , Paolo Gontero  2 , Umberto Ricardi  3 , Désirée Deandreis  1
Affiliations

Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence

Guido Rovera et al. Diagnostics (Basel). .

Abstract

Prostate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) can accurately detect disease localizations in prostate cancer (PCa) patients with early biochemical recurrence/persistence (BCR/BCP), allowing for more personalized image-guided treatments in oligometastatic patients with major impact in the case of bone metastases (BM). Therefore, this study aimed to identify predictors of BM at PSMA-PET in early-BCR/BCP hormone-sensitive PCa (HSPC) patients, previously treated with radical intent (radiotherapy or radical prostatectomy ± salvage-radiotherapy (SRT)). A retrospective analysis was performed on 443 68Ga-PSMA-11-PET/CT scans. The cohort median PSA at PET-scan was 0.60 (IQR: 0.38-1.04) ng/mL. PSMA-PET detection rate was 42.0% (186/443), and distant lesions (M1a/b/c) were found in 17.6% (78/443) of cases. BM (M1b) were present in 9.9% (44/443) of cases, with 70.5% (31/44) showing oligometastatic spread (≤3 PSMA-positive lesions). In the multivariate binary logistic regression model (accuracy: 71.2%, Nagelkerke-R2: 13%), T stage ≥ 3a (OR: 2.52; 95% CI: 1.13-5.60; p = 0.024), clinical setting (previous SRT vs. first-time BCR OR: 2.90; 95% CI: 1.32-6.35; p = 0.008), and PSAdt (OR: 0.93; 95% CI: 0.88-0.99; p = 0.026) were proven to be significant predictors of bone metastases, with a 7% risk increment for each single-unit decrement of PSAdt. These predictors could be used to further refine the indication for PSMA-PET in early BCR/BCP HSPC patients, leading to higher detection rates of bone disease and more personalized treatments.

Keywords: PSMA PET; bone disease; hormone-sensitive prostate cancer; predictive model; prostatic neoplasm.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PSMA-PET results according to miTNM classification (N = 443).
Figure 2
Figure 2
Bone metastases prevalence at PSMA-PET, stratified by clinical setting (N = 443).
See this image and copyright information in PMC

References

    1. Beresford M.J., Gillatt D., Benson R.J., Ajithkumar T. A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-Prostatectomy Biochemical Recurrence. Clin. Oncol. 2010;22:46–55. doi: 10.1016/j.clon.2009.10.015. - DOI - PubMed
    1. Hofman M.S., Lawrentschuk N., Francis R.J., Tang C., Vela I., Thomas P., Rutherford N., Martin J.M., Frydenberg M., Shakher R., et al. Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (ProPSMA): A Prospective, Randomised, Multicentre Study. Lancet. 2020;395:1208–1216. doi: 10.1016/S0140-6736(20)30314-7. - DOI - PubMed
    1. Ferraro D.A., Garcia Schüler H.I., Muehlematter U.J., Eberli D., Müller J., Müller A., Gablinger R., Kranzbühler H., Omlin A., Kaufmann P.A., et al. Impact of 68Ga-PSMA-11 PET Staging on Clinical Decision-Making in Patients with Intermediate or High-Risk Prostate Cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020;47:652–664. doi: 10.1007/s00259-019-04568-1. - DOI - PubMed
    1. Emmett L., Metser U., Bauman G., Hicks R.J., Weickhardt A., Davis I.D., Punwani S., Pond G., Chua S., Ho B., et al. Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. J. Nucl. Med. 2019;60:794–800. doi: 10.2967/jnumed.118.220103. - DOI - PMC - PubMed
    1. Calais J., Ceci F., Eiber M., Hope T.A., Hofman M.S., Rischpler C., Bach-Gansmo T., Nanni C., Savir-Baruch B., Elashoff D., et al. 18F-Fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence after Prostatectomy: A Prospective, Single-Centre, Single-Arm, Comparative Imaging Trial. Lancet Oncol. 2019;20:1286–1294. doi: 10.1016/S1470-2045(19)30415-2. - DOI - PMC - PubMed